Trial reportBritish journal of cancer2009
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer.
Trial report in British journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01019798 (Phase II Study of Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer), which is not on this map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.Journal of the National Cancer Institute · 2016Pooled it
- Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.Targeted oncology · 2013Pooled it
- Trial
- Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer.BMC cancer · 2015Trial
- Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.British journal of cancer · 2014Trial
- CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2014Trial
- A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).Annals of oncology : official journal of the European Society for Medical Oncology · 2013Trial
- Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.Investigational new drugs · 2012Trial
- Phase II study of sunitinib malate in patients with recurrent high-grade glioma.Journal of neuro-oncology · 2011Trial
- Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population.Medical oncology (Northwood, London, England) · 2011Trial
- Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer.Exploration of targeted anti-tumor therapy · 2020Review
- Acquired tumor cell resistance to sunitinib by increased invasion and epithelial-mesenchymal transition in LL/2 murine lung cancer.Oncotarget · 2017Article
- Synthesis and Antitumor Activity of 5-Bromo-7-azaindolin-2-one Derivatives Containing a 2,4-Dimethyl-1H-pyrrole-3-carboxamide Moiety.Molecules (Basel, Switzerland) · 2016Article
- The green tea polyphenol EGCG potentiates the antiproliferative activity of sunitinib in human cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- The role of anti-angiogenesis in non-small-cell lung cancer: an update.Current oncology reports · 2015Review
- Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.British journal of clinical pharmacology · 2015Article
- Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours.Current oncology (Toronto, Ont.) · 2014Review
- Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors.Translational oncology · 2014Article
- Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Clinical pharmacokinetics · 2014Review
- [Progress of platelet derived grow factor family in non-small cell lung cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2014Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment) in advanced non-small cell lung cancer (NSCLC).
methodsWe examined the activity of sunitinib on a continuous daily dosing (CDD) schedule in an open-label, multicentre phase II study in patients with previously treated, advanced NSCLC. Patients > or =18 years with stage IIIB/IV NSCLC after failure with platinum-based chemotherapy, received sunitinib 37.5 mg per day. The primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), 1-year survival rate, and safety.
resultsOf 47 patients receiving sunitinib, one patient achieved a confirmed partial response (ORR 2.1% (95% confidence interval (CI) 0.1, 11.3)) and 11 (23.4%) had stable disease (SD) > or =8 weeks. Five patients had SD>6 months. Median PFS was 11.9 weeks (95% CI 8.6, 14.1) and median OS was 37.1 weeks (95% CI 31.1, 69.7). The 1-year survival probability was 38.4% (95% CI 24.2, 52.5). Treatment was generally well tolerated.
conclusionsThe safety profile and time-to-event analyses, albeit relatively low response rate of 2%, suggest single-agent sunitinib on a CDD schedule may be a potential therapeutic agent for patients with advanced, refractory NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.